Merck & Co., Inc. stock (US58933Y1055): Q1 beat and upgraded 2026 guidance drive 8% jump

Merck & Co., Inc. stock jumped 8% to a two-month high following the release of first-quarter 2026 results that exceeded forecasts, coupled with an upgraded full-year 2026 guidance. The pharmaceutical giant reported robust revenue growth, with sales reaching US$16,286 million for the quarter, despite a net loss of US$4,240 million influenced by acquisition-related costs, Simply Wall St as of May 2026. Additionally, Keytruda-related deals bolstered investor confidence in the company's oncology franchise.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Merck & Co., Inc.: core business model

Merck & Co., Inc. operates as a leading global healthcare company focused on discovering, developing, manufacturing, and marketing innovative medicines and vaccines. The company maintains a diversified portfolio spanning human health pharmaceutical products, vaccines, and animal health solutions. Key products like Keytruda, an immunotherapy for various cancers, represent a cornerstone of its revenue stream, contributing significantly to growth in the US market where oncology demand remains high.

Merck & Co., Inc. invests heavily in research and development, with a pipeline targeting oncology, immunology, and infectious diseases. This R&D focus supports long-term sustainability, particularly for US investors tracking exposure to the $500+ billion US pharmaceutical sector, according to Merck as of May 2026.

Main revenue and product drivers for Merck & Co., Inc.

Oncology drugs, led by Keytruda, drove much of the recent quarterly performance, with ongoing deals enhancing future prospects. Vaccines and animal health segments also provide stable contributions, with Q1 2026 revenue up overall on a year-over-year basis at 4.9% in related metrics, as noted in filings, MarketBeat as of 05/13/2026. These drivers underscore Merck & Co., Inc.'s resilience amid patent cliffs and competitive pressures.

The upgraded 2026 guidance reflects confidence in sustained demand for blockbuster products, vital for US-listed pharma stocks amid economic exposure to healthcare spending.

Conclusion

Merck & Co., Inc. demonstrated solid Q1 2026 performance with revenue beats and raised guidance, propelling shares higher amid focus on oncology leaders like Keytruda. While acquisition costs impacted net figures, core operational strength persists, offering relevant exposure for US investors in the healthcare sector. Market dynamics, including regulatory and competitive factors, will shape near-term trajectories.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.